Teva Real-World Study Shows UZEDY Outperforms Long-Acting Injectables
Resolved · regulation · Occurred · Assessed · 2 sources
This assessment is dated 2026-09-19. Check what remains unresolved below before relying on it.
Which companies' revenue or costs change?
Superior real-world clinical persistence expands commercial formulary tier access and supports TEVA branded specialty revenue trajectory.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factTeva announced real-world evidence demonstrating UZEDY (risperidone extended-release) superior treatment continuity in schizophrenia compared to competing long-acting injectables. |
| What else was confirmed? | Reported factThe data showed UZEDY reduced emergency care visits and overall healthcare expenditures for patients with schizophrenia and bipolar I disorder. |
| Does the valuation support acting? | Interpretation3 stored valuation assumptions for TEVA; the latest is dated 2026-09-11. |
| What would change the assessment? | UnknownTEVA specialty pharmaceutical sales commentary — Quarterly prescription volume updates for UZEDY and AUSTEDO |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Teva announced real-world evidence demonstrating UZEDY (risperidone extended-release) superior treatment continuity in schizophrenia compared to competing long-acting injectables.
- · The data showed UZEDY reduced emergency care visits and overall healthcare expenditures for patients with schizophrenia and bipolar I disorder.
- · Teva also reported separate data highlighting AUSTEDO (deutetrabenazine) alignment with clinician priorities in treating tardive dyskinesia in patients aged 55 and older.
Public research record
Research framework · page evidenceCompleted event assessment
specialty brand revenue growth via improved payer formulary placement
| Type | Claim | Scope |
|---|---|---|
| Assumption | Teva announced real-world evidence demonstrating UZEDY (risperidone extended-release) superior treatment continuity in schizophrenia compared to competing long-acting injectables. | 2026-09-19 |
| Interpretation | specialty brand revenue growth via improved payer formulary placement | TEVA |
Countercase, invalidators, and sources
Payer formularies expand preferred coverage for UZEDY based on emergency room cost reduction metrics.
- · TEVA specialty pharmaceutical sales commentary — Quarterly prescription volume updates for UZEDY and AUSTEDO
- Teva Highlights New Real-World Data Showing UZEDY Outperforms Other Long-Acting Injectables · 2026-09-18
What remains unresolved
- Base path
- UZEDY adoption continues steady quarterly prescription volume growth across institutional psychiatry centers.
- Adverse path
- Generic competition and pricing pressure in adjacent neurology franchises offset specialty volume gains.
- Supportive path
- Payer formularies expand preferred coverage for UZEDY based on emergency room cost reduction metrics.
- · TEVA specialty pharmaceutical sales commentary — Quarterly prescription volume updates for UZEDY and AUSTEDOthis week
Evidence
- Teva Highlights New Real-World Data Showing UZEDY Outperforms Other Long-Acting Injectables2026-09-18
“Teva announced real-world data demonstrating that UZEDY (risperidone) extended-release injectable suspension shows superior treatment continuity compared to other long-acting injectables in schizophrenia patients”
Supports: UZEDY demonstrated superior treatment continuity and reduced emergency healthcare costs in schizophrenia and bipolar I disorder.